U.S. pharma giant copyright scrapped two experimental weight loss drugs final yr—a at the time-everyday pill, lotiglipron, because of elevated liver enzymes and a 2 times-day by day pill, danuglipron, on account of strong Negative effects—but CEO Albert Bourla has reported the company is decided to “Participate in and win” during the being